

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**INSIDE INFORMATION**

**RESULTS FORECAST FOR THE YEAR 2023**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

**I. Results Forecast**

**A. Period of the results forecast**

The period of the results forecast is from January 1, 2023 to December 31, 2023 (the “**Reporting Period**”).

**B. Details of the results forecast**

1. According to the preliminary estimation of the Company, the net loss attributable to the shareholders of the Company for the year ended December 31, 2023 is expected to be RMB1,268.5 million to RMB1,496.9 million.
2. The net loss attributable to the shareholders of the Company after deducting the non-recurring profit or loss for the year ended December 31, 2023 is expected to be RMB1,377.0 million to RMB1,624.9 million.

**C. Preliminary audit of the results forecast**

This results forecast has not been audited or reviewed by independent auditors.

**II. Performance in the corresponding period in the last year**

During the corresponding period in 2022, according to PRC Generally Accepted Accounting Principles, the net loss attributable to the shareholders of the Company was approximately RMB909.4 million; the net loss attributable to the shareholders of the Company after deducting non-recurring profit or loss was approximately RMB1,033.2 million.

### III. Reasons for changes in results

During the Reporting Period, revenue from sales of meningococcal vaccines increased significantly compared with corresponding period last year, as the Group made progress in the commercialization, product promotion and marketing of the meningococcal vaccines. The Group's Menhycia® is the first MCV4 vaccine product in China positioned at the high-end market of vaccines not covered by the immunization program for infants, aiming to provide better solutions for the prevention of infant meningococcal meningitis.

The increase in the net loss attributable to the shareholders of the Company was mainly due to the following: revenue of COVID-19 vaccines decreased significantly compared with corresponding period last year, which was due to the change in the market demand for COVID-19 vaccines. Based on the actual vaccination status of COVID-19 vaccines and expectations for future vaccinations, the Group has accounted for and reasonably estimated the sales return amount incurred and expected to be incurred for COVID-19 vaccines, and has deducted the revenue of COVID-19 vaccines during the Reporting Period. In terms of the operating cost, due to the low production volume of COVID-19 vaccines and under-utilization rate of relevant manufacturing capacity, the Group has recognized the fixed costs associated with the redundant production capacity in operating costs. Considering the future utilization plan of inventories and long-term assets related to COVID-19 vaccines, the Group conducted impairment test on inventories, right to returned goods asset, prepayments and long-term assets with impairment indicators, and recognized provision based on the test results. Meanwhile, during the Reporting Period, the Group has increased the marketing activities for the continuous promotion of meningococcal vaccines, resulting in an increase in selling expenses as compared with corresponding period last year.

### IV. Risk Factors

The Company does not have any significant uncertainty factors that may affect the accuracy of the results forecast.

### V. Other Information

The results forecast above is only a preliminary calculation performed by the Company and the specific and accurate financial data shall be subject to the audited annual report of 2023 officially disclosed by the Company. Investors are reminded to exercise caution when making investment decisions.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
Chairman

Hong Kong, January 30, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*